In a randomized controlled trial of adults with Rome IV irritable bowel syndrome without constipation, investigators found that a Mediterranean-style low-FODMAP diet produced greater symptom improvement,...
A randomized, double-blind trial evaluated whether 4 commonly used nutritional supplements could improve symptoms or microbiota-related outcomes in adults with irritable bowel syndrome.
New research shows stalled childhood vaccine progress, elevated heart risks linked to COVID-19 vaccines in young men, and rising gastrointestinal disorders during the pandemic.
Researchers examined the presence of undiagnosed severe exocrine pancreatic insufficiency in individuals with irritable bowel syndrome plus diarrhea, as well as the associated symptoms and the impact of...
The authors of a new study evaluated more than 4000 cases of Campylobacter infection to estimate the US incidence of Campylobacter infection–associated postinfectious irritable bowel syndrome.
The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
After a clinical trial showed the device was more effective than placebo, the FDA permitted marketing for the medical device that assists in the reduction of functional abdominal pain among adolescents with...
By analyzing patient measurements of symptom severity and disease-specific quality of life, researchers determined the effect of pathophysiologic factors on irritable bowel syndrome outcomes.
Because irritable bowel syndrome is thought to be due to a disorder of brain–gut function, Dr Brian Lacy from Mayo Clinic and colleagues evaluated whether drugs acting centrally are effective in treating...
